Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain
- 23 Downloads
Background and Objectives
Oxycodone tamper resistant (OTR) is a new extended-release abuse-deterrent formulation providing improvements in the tamper resistant characteristics. This study aimed to investigate the pharmacokinetic properties of the new OTR tablets and evaluate the bioequivalence of oxycodone from OTR and the original extended release (ER) formulation tablets administered with an opioid antagonist in patients with chronic pain.
In this open-label, randomized, cross-over study, the enrolled patients were randomised to receive a single dose of 40 mg OTR or 40 mg OXYCONTIN® (OXY) tablet administered with naltrexone blockade under fasting conditions. Serial blood samples for pharmacokinetic analysis were collected. Plasma oxycodone was quantified by a high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) method. Tolerability was evaluated by monitoring adverse events, physical examinations, 12-lead ECG and laboratory tests.
A total of 38 patients were enrolled and 33 subjects completed the study. After a single dose of 40 mg tablets, pharmacokinetic results of the new OTR tablet were found to be similar to those of original extended-release oxycodone tablet. OTR 40 mg was bioequivalent to OXY 40 mg and was well tolerated in patients with chronic pain.
The new OTR formulation could provide a new choice in the treatment of chronic pain and reduce the potential for oxycodone abuse.
Chictr.org identifier: ChiCTR1800017253.
Compliance with Ethical Standards
The study was sponsored and funded by Mundipharma (China) Pharmaceutical Co. Ltd. (Beijing, People’s Republic of China).
Conflict of interest
The authors have declared that no financial relationships with any organizations that might have an interest in the submitted work; no other relationships or activities that could influence the submitted work.
The study protocol was approved by the Independent Ethics Committee of West China Hospital, Sichuan University (Chengdu, China). All procedures in this study were carried out in accordance with the Helsinki declaration.
Written informed consent was obtained from each subject before screening procedures.
- 3.The Medical Letter Inc. Abuse-deterrent opioids. Med Lett Drugs Ther. 2017;59(1522):95–6.Google Scholar
- 8.Investigator’s Brochure of Oxycodone Tamper Resistant (Reformulated Oxycontin), Purdue Pharma, released date Jun/2016, edition number 16.1.Google Scholar
- 10.Bioavailability and bioequivalence studies submitted in NDAs or INDs-general considerations. US FDA. 2014. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-and-bioequivalence-studies-submitted-ndas-or-inds-general-considerations. Accessed 16 Oct 2019.
- 11.Pain and Policy Studies Group. Opioid consumption data. https://ppsg-chart.medicine.wisc.edu/. Accessed 1 Jan 2019.
- 12.U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Abusedeterrent opioids—evaluation and labeling: guidance for industry. Silver Spring: US DoH; 2015.Google Scholar
- 13.OxyContin (oxycodone hydrochloride) extended-release tablets [package insert]. Stamford (CT): Purdue Pharma L.P.; 2016.Google Scholar
- 20.Alexander SPH, Mathie A, Peters JA. Guide to receptors and channels (GRAC), 4th edn. Br J Pharmacol. 2009;158(Suppl. 1):S1–25.Google Scholar
- 37.Franke RM, Morton T, Devarakonda K. Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets. Drug Des Dev Ther. 2015;9:4587–97.Google Scholar